Restricted accessCase reportFirst published online 2023-2
Bictegravir/emtricitabine/tenofovir alafenamide in a virologically suppressed adult with HIV and end-stage renal disease on chronic peritoneal dialysis: A case report
Despite increasing rates of renal replacement therapy, data supporting the safe and effective use of HIV treatment guidelines preferred regimens in people on hemodialysis or peritoneal dialysis is limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a guideline recommended initial regimen for most people with HIV with FDA-approval for use in virologically suppressed people receiving chronic hemodialysis; however, the safety and efficacy of BIC/FTC/TAF remains unknown when used in patients on chronic ambulatory peritoneal dialysis (CAPD). We report the first case of BIC/FTC/TAF use in CAPD.
AbrahamAGAlthoffKNJingY, et al.End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis2015; 60: 941–949.
2.
LucasGMRossMJStockPG, et al.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis2014; 59: e96–e138. DOI: 10.1093/cid/ciu617
3.
EkrikpoUEKengneAPBelloAK, et al.Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS One2018; 13: e0195443. DOI: 10.1371/journal.pone.0195443
4.
NaickerSRahmanianSKoppJB. HIV and chronic kidney disease. Clin Nephrol2015; 83: 32–38.
5.
HeronJEBagnisCIGraceyDM. Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV. AIDS Res Ther2020; 17: 11. DOI: 10.1186/s12981-020-00266-3
6.
DandachiDFabriciusMSaadB, et al.Antiretrovirals for people with HIV on dialysis. AIDS Patient Care and STDs2022; 36: 86–96.
7.
Gilead Sciences. Biktarvy (Package Insert). Foster City, CA, USA: Gilead Sciences, 2021.
8.
EronJJWilkinARamgopalM, et al.A daily single tablet regimen (STR) of bictegravir/emtricitabine/tenofovir alafenamide (b/F/TAF) in virologically-suppressed adults living with HIV and end stage renal disease on chronic hemodialysis. Open Forum Infect Dis2020; 7: S529–S530. DOI: 10.1093/ofid/ofaa439.1188
9.
CollinsAJ. Introduction. Home Dial Jpn2012; 177: 1–2.
10.
MurphyJE. Clinical pharmacokinetics. 6th ed. Bethesda, MA, USA: American Society of Health-System Pharmacists, Inc., 2021, pp. 31–37.
11.
SteublDRoosMHettwerS, et al.Comparison of peritoneal low-molecular-weight-protein-removal in CCPD and CAPD patients based on C-terminal agrin fragment clearance. Kidney Blood Press Res2016; 41: 175–185.
12.
JanknegtRKoelmanJH. Drug therapy in continuous ambulatory peritoneal dialysis patients. Pharmaceutisch Weekblad Scientific Edition1987; 9: 104–109.
CustodioJMFordyceMGarnerW, et al.Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother2016; 60: 5135–5140.
24.
D:A:D Study Group, SabinCASigneWW, et al.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet2008; 371: 1417–1426.
25.
RyomLLundgrenJDEl-SadrW, et al.Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. The Lancet HIV2018; 5: e291–e300. DOI: 10.1016/s2352-3018(18)30043-2
26.
MaggioloFRizzardiniGMolinaJM, et al.Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with hiv: results of a 96 week, phase 3B, open‐label, switch trial in virologically suppressed people ≥65 years of age. HIV Med2022. Epub ahead of print 2022. DOI: 10.1111/hiv.13319
27.
NachegaJBParientiJ-JUthmanOA, et al.Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis2014; 58: 1297–1307.
28.
RamjanRCalmyAVitoriaM, et al.Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health2014; 19: 501–513.
